


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED

中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

**VOLUNTARY ANNOUNCEMENT
APPOINTMENT OF CHIEF MEDICAL OFFICER**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that, Professor Mao Li has been appointed as the Chief Medical Officer by the Company. He will be mainly responsible for formulating research and development strategy of innovative products, directing translational research and clinical development for innovative product pipelines, and promoting international collaborations.

Professor Mao Li (“**Professor Mao**”) is a world-renowned expert in the field of oncology, who has established Johnson & Johnson’s global lung cancer research center across three business areas, with more than 35 years of clinical practice, basic research and leadership experience in oncology. He obtained a degree in clinical medicine from Nanjing Medical University, and completed post-doctoral research and studies at Mayo Hospital and The Johns Hopkins University School of Medicine in the United States. Professor Mao was honored as a tenured professor at the MD Anderson Cancer Center at the University of Texas, and the chair of the Department of Oncology and Diagnostics at the University of Maryland. Professor Mao has made significant contributions in the research of tumor molecular biology mechanism, molecular diagnosis and precision treatment, and has profound academic attainments; he has published more than 200 SCI (Science Citation Index) papers, which have been cited more than 25,000 times. He served as editor and editorial board member of many international professional journals, as well as member of the judging panel of multiple funds of the National Institutes of Health of the United States. Professor Mao Li was once employed as an expert on the National High-level Talents Program and a Yangtze River scholar lecture professor of the Shanghai Jiaotong University School of Medicine. He has also successively held senior management positions in Johnson & Johnson in the United States and other large pharmaceutical companies, led a number of clinical registration studies and completed many applications for new drug certificate.

The Group has always attached great importance to the research and development and innovation of new drugs. With the joining of Professor Mao, the Group believes that his outstanding research capabilities, rich management experience and academic achievements, which are widely recognized by the industry globally, will be of great benefit to the Group's new product research and development, technology translation and international collaboration mainly in the field of oncology, and will also contribute to the Group's innovation drive and internationalization strategy.

By order of the Board
Sino Biopharmaceutical Limited
Chairwoman
Tse, Theresa Y Y

Hong Kong, 10 May 2021

As at the date of this announcement, the Board of the Company comprises nine Executive Directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and five Independent Non-Executive Directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Mr. Li Kwok Tung Donald.